Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study

Martin Miguel; Loibl Sibylle; von Minckwitz Gunter; Morales Serafin; Martinez Noelia; Guerrero Angel; Anton Antonio; Aktas Bahriye; Schoenegg Winfried; Munoz Montserrat; Angel Garcia-Saenz Jose; Gil Miguel; Ramos Manuel; Margeli Mireia; Carrasco Eva; Liedtke Cornelia; Wachsmann Grischa; Mehta Keyur; De la Haba-Rodriguez Juan R.

首页> 外文期刊>Journal of Clinical Oncology >Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study

【24h】

Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study

机译：评估贝伐单抗在内分泌治疗中作为晚期乳腺癌的一线治疗的第三阶段试验：来曲唑/氟维司群和阿瓦斯汀（LEA）研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2015年第9期|共11页
作者
Martin Miguel; Loibl Sibylle; von Minckwitz Gunter; Morales Serafin; Martinez Noelia; Guerrero Angel; Anton Antonio; Aktas Bahriye; Schoenegg Winfried; Munoz Montserrat; Angel Garcia-Saenz Jose; Gil Miguel; Ramos Manuel; Margeli Mireia; Carrasco Eva; Liedtke Cornelia; Wachsmann Grischa; Mehta Keyur; De la Haba-Rodriguez Juan R.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study [J] . Martin Miguel, Loibl Sibylle, von Minckwitz Gunter, Journal of Clinical Oncology . 2015,第9期

机译：评估贝伐单抗在内分泌治疗中作为晚期乳腺癌的一线治疗的第三阶段试验：来曲唑/氟维司群和阿瓦斯汀（LEA）研究
2. The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer. [J] . G Bisagni, A Musolino, M Panebianco, Cancer chemotherapy and pharmacology. . 2013,第4期

机译：乳腺阿瓦斯汀试验：贝伐单抗维持治疗II期研究多西他赛和卡培他滨诱导化疗后用于局部复发或转移性乳腺癌患者的一线治疗。
3. The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer. [J] . G Bisagni, A Musolino, M Panebianco, Cancer chemotherapy and pharmacology. . 2013,第4期

机译：乳腺Avastin试验：II期贝伐单抗维持治疗诱导化疗后的多西紫杉醇和Capecitabine进行局部复发性或转移性乳腺癌患者的一线治疗。
4. Nanosecond, low voltage electro-endocrine-therapy for breast cancer treatment [C] . Funian Xiao, Leary J.F., Reece L., 2010 Annual Report Conference on Electrical Insulation and Dielectric Phenomena . 2010

机译：纳秒级低压电内分泌疗法，用于乳腺癌治疗
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor–Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance) [O] . Maura N. Dickler, William T. Barry, Constance T. Cirrincione, -1

机译：评估来曲唑作为一线内分泌治疗方案（有或没有贝伐单抗）治疗激素受体阳性晚期乳腺癌的绝经后妇女的第三阶段试验：CALGB 40503（联盟）
7. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor–positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials [O] . M. Martín, S. Loibl, T. Hyslop, 2019

机译：评估Bevacizumab以内分泌治疗作为激素受体阳性转移性乳腺癌的一线治疗：来自LEA的汇总分析（Geicam / 2006-11_GBG51）和CalgB 40503（联盟）试验

Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study

摘要

著录项

相似文献

相关主题

期刊订阅